7JN.F POOLBEG PHARMA LS -0002

Healthcare Biotechnology Frankfurt Exchange
0.0580 EUR
Close of Nov 11, 2026
0.0305 0.1110
Market cap
EUR 44.3M
P/E
-
P/B
5.79x
ROE
-66.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 7JN.F undervalued?

Graham number

The Graham number of POOLBEG PHARMA LS -0002 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

POOLBEG PHARMA LS -0002 fundamental analysis

No fundamental analysis for POOLBEG PHARMA LS -0002 yet.

POOLBEG PHARMA LS -0002 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About POOLBEG PHARMA LS -0002

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza …

Full company profile